To conclude, our study points at PRMT6 as an attractive target for cancer drug therapy, suggesting that PRMT6 inhibitors should be tested preferentially in selected subgroups of cancer that have fewer therapeutic alternatives due, for example, to an inactive p53 pathway and low expression of p21. The gene discussed is TP53; the disease is cancer.